BioCurex, Inc.(fka BOCX)

[cannonball2010]

green baron comment about the recent research report

The Green Baron Report does its best to boil down the most important points to focus on when we choose a stock for our members. Our staff has carefully researched and combed through tremendous amounts of information and data so you won’t have to. We choose only the best of the best stock picks we can find only after careful analysis. BioCurex has an incredible story, and it could take reading over 20 pages to gain a better understanding of this Company. Well, if you feel compelled to read this type of report on BioCurex, we strongly suggest our members follow the link in the reprinted press release below and attain a copy.

In our opinion, we note that the projected target price of $2.17 is based on extremely conservative numbers. The writer of this report was not privy to information that might have caused him to significantly increase this number. We at The Green Baron Report do not have access to such numbers either, but our conversations with management and others indicate that much higher prices in the stock are anticipated and warranted.

Technically, BOCX is showing signs of improvement. The closing price of $1.24 per share is the highest close we have seen since our initial profile earlier this month at .97 per share. Stochastic indicators appear to have recently bottomed again, and the increased volume seems to support that a bigger move up is coming.

July 26, 2005 - BioCurex Inc. wishes to advise its shareholders of the availability of an independent research report on the Company prepared by Emergent Growth Analytics Research. The report strictly represents the views of the analyst concerning Biocurex. The report is available at http://www.smallcapnetwork.net/bocx_signup.html concerning BioCurex. The information may be of interest to the shareholders of BioCurex and the link to the report is provided for their benefit.

BioCurex is advancing in its corporate goals and will provide the appropriate updates. The Company is pleased to note that it is receiving increasing attention for its patented/proprietary technology for the detection of many types of cancer with a basic blood test.

BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the receptor for alpha-fetoprotein, RECAF has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. RECAF is found on malignant cells from a variety of cancer cell types but is absent in most normal and benign cells. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others. Abbott's goal is to further develop this technology, incorporating it into future tests on their ARCHITECT(r) system, for use in cancer diagnosis and monitoring.